Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Knosys secures an additional one-year contract with Optus for over $1 million
    • News

    Knosys secures an additional one-year contract with Optus for over $1 million

    How many tabs do you shuffle across every day? Probably more than you need to. Covid and hybrid work have given rise to a slew of online tools, all designed to help you improve your work processes. However, the need of the hour is not to diversify the tool suite but to streamline it.  That’s

    Read More
    Public
  • Revenue, profit and debt – understanding the relevance of each when investing in shares
    • Explainers

    Revenue, profit and debt – understanding the relevance of each when investing in shares

    When looking at companies to invest in on a sharemarket like the ASX in Australia, it is important to understand the relevancy of revenue, debt and profit. These three financial metrics can provide valuable insight into a company’s financial health and potential for growth. Revenue is the amount of money a company brings in from

    Read More
    Public
  • Atomo Diagnostics to launch pregnancy tests as demand for Covid antigen tests peters out
    • News

    Atomo Diagnostics to launch pregnancy tests as demand for Covid antigen tests peters out

    As Covid fizzled out, the share price of medical device company Atomo Diagnostics (ASX: AT1) did, too, falling from $0.50 per share in 2020 to $0.059 today. However, the Company is not about to breathe its last with this slump. Instead, it is pivoting to a new diagnostic test—one expected to be worth around $3

    Read More
    Public
  • MVP discontinues clinical trials in China for Green Whistle, focuses on growth in the US
    • News

    MVP discontinues clinical trials in China for Green Whistle, focuses on growth in the US

    Perhaps China decided to make its own version of the drug or perhaps it proved that it could do so and fast. Whatever it may be, something told the specialised healthcare company Medical Developments International Limited (ASX: MVP) that it wasn’t a good idea to continue pursuing the country. And so, it stopped. Medical Developments

    Read More
    Public
  • Incannex Healthcare paves the way for novel mental health treatments
    • News

    Incannex Healthcare paves the way for novel mental health treatments

    Incannex Healthcare (ASX: IHL) has reported interim data from its Phase 2 clinical trials to treat anxiety through the use of psychedelics. Upon completion of the trials, the Company will seek to progress this new therapy and offer renewed hope for individuals seeking non-pharmacological solutions to treat mental health.  Psilocybin-assisted psychotherapy has emerged as the

    Read More
    Public
  • Aussie cancer researcher primed for 2023 with groundbreaking clinical trial data releases scheduled
    • News

    Aussie cancer researcher primed for 2023 with groundbreaking clinical trial data releases scheduled

    Aussies are some of the most enthusiastic adopters of new clinical drugs. In 2019, 95,000 of us participated in nearly 2,000 clinical trials where Australia is home to many of the world’s leading scientists. In keeping with that, clinical stage biotech company Pharmaxis (ASX: PXS) has a thriving drug development pipeline set to report clinical

    Read More
    Public
  • «
  • ‹
  • 291
  • 292
  • 293
  • 294
  • 295
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.